ArticleScientific reports2026
Platform design of hybrid microphysiological system integrating in vitro and in silico models for reproducing insulin-regulated glucose metabolism.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study presents a hybrid platform for microphysiological systems (MPS) that combines in vitro organ-on-a-chip (OoC) technology and an in silico model. In this platform, in silico models act as virtual organs that interact with real OoCs, enabling the stimulation of multi-organ interactions without physically preparing all surrounding OoCs. Generally, replicating organ interactions in the body requires the preparation of various cultured cell types. However, co-culturing cells results in complex specifications and methods for the MPS. In contrast, this study proposes a hybrid design of real OoCs and in silico models for multi-organ applications. An OoC model of skeletal muscle (SM) integrated with an in silico insulin controller was developed for a glucose metabolism system that responds to insulin action. The platform consists of a real SM OoC and an in silico insulin control model. A lab-on-a-chip device was designed for the real SM OoC that enables feedback control by automated culture, insulin dosing, and glucose monitoring. An in silico architecture was developed to enable the installation of various mathematical models into an in silico controller. The proposed cybernetic MPS platform facilitates the efficient preparation of multiorgan models that enhance in vitro drug testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.